Yong Yu - Feb 19, 2024 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Sean Ryder, Esq., Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
Feb 19, 2024
Transactions value $
-$14,520
Form type
4
Date filed
7/8/2024, 04:30 PM
Previous filing
Dec 18, 2023
Next filing
Jun 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Award $0 +3.66K +146.44% $0.00 6.16K Feb 19, 2024 Direct F1
transaction GNLX Common Stock Award $0 +11.6K +187.58% $0.00 17.7K Mar 14, 2024 Direct F2
transaction GNLX Common Stock Sale -$14.5K -6.85K -38.66% $2.12 10.9K Jun 24, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.
F2 Represents RSUs that are fully vested as of March 14, 2024.
F3 Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of RSUs.